NCTN: A Randomized Phase III Trial of CC-5013 (Lenalidomide) and Low Dose Dexamethasone (LLD) versus Bortezomib, Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma (S0777)
Getting access
No access information recorded yet.
About this database
| Last updated | 2026-08-25 |
|---|